Price$7.88+1.47 (+22.92%)
2026-05-202026-08-24
News · 26 weeks61+175%
2026-03-012026-08-23
Mix1790d
- SEC Filings7(41%)
- Other4(24%)
- Leadership3(18%)
- Insider2(12%)
- Earnings1(6%)
Latest news
25 items- INSIDERDirector Gabay Avraham was granted 13,643 units of Ordinary Shares (SEC Form 4)4 - Lifeward Ltd. (0001607962) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gabay Avraham3 - Lifeward Ltd. (0001607962) (Issuer)
- SECLifeward Ltd. filed SEC Form 8-K: Leadership Update8-K - Lifeward Ltd. (0001607962) (Filer)
- PRNano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation CommitteeWALTHAM, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension," "Nano," or the "Company") today announced the appointment of Nadav Kidron to its Board of Directors (the "Board"). As part of the Board’s ongoing strategic review, led by Chairman Phillip Borenstein, the Board intends to establish a Strategy and Capital Allocation Committee to support the Board’s evaluation of capital allocation alternatives, potential returns of excess capital to shareholders, monetization of non-core assets, strategic opportunities and other initiatives intended to maximize long-term shareholder value. Mr. Kidron will chair this committee and work with the Chairman, hi
- SECSEC Form 10-Q filed by Lifeward Ltd.10-Q - Lifeward Ltd. (0001607962) (Filer)
- SECLifeward Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Lifeward Ltd. (0001607962) (Filer)
- PRLifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives GrowthRevenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support continued commercial execution HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today reported financial results for the second quarter ended June 30, 2026. Corporate & Financial Highlights Revenue increased 16% to $6.6 million in the second quarter of 2026 compared to the second quarter of
- SECSEC Form EFFECT filed by Lifeward Ltd.EFFECT - Lifeward Ltd. (0001607962) (Filer)
- PRLifeward to Report Second Quarter 2026 Financial Results on August 14, 2026HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its second quarter 2026 financial results on Friday, August 14, 2026. A press release will be issued and quarterly report will be filed with the SEC prior to 9:30 a.m. ET. The Company will not conduct a conference call. About Lifeward Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfoli
- PRLifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal ExoskeletonOttobock Care, one of the leading mobility technology patient care organizations in the U.S., brings extensive clinical expertise and patient care infrastructure Advances Lifeward’s strategy to broaden ReWalk access through capital-efficient channel partner model intended to accelerate growth, expand patient access and improve commercial scalability HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the launch of a pilot program with Ottobock Care, one of th
- SECSEC Form S-3 filed by Lifeward Ltd.S-3 - Lifeward Ltd. (0001607962) (Filer)
- PRNano Dimension Announces Appointment of Interim Chief Executive Officer and Chairman of the BoardWALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension," "Nano", or the "Company") today announced the appointment of Moshe Rozenbaum as Interim Chief Executive Officer ("CEO"), effective immediately. The Company’s Board of Directors (the "Board") has also appointed Phillip Borenstein as Chairman of the Board. Mr. Rozenbaum will work closely with the Board and the Company’s leadership to support business continuity while the Board evaluates the Company’s strategic priorities and opportunities moving forward. Phillip Borenstein, Chairman of the Board, commented, "On behalf of myself and the entire Board of Directors, we are pleased to appoint
- SECSEC Form D filed by Lifeward Ltd.D - Lifeward Ltd. (0001607962) (Filer)
- SECLifeward Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Lifeward Ltd. (0001607962) (Filer)
- PRLifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic FinancingHUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that it has entered into a securities purchase agreement with a group of institutional and accredited investors participating in the strategic financing framework established earlier this year with Oramed Pharmaceuticals (NASDAQ:ORMP). "This financing reflects confidence in our strategy and the opportunity ahead," said Mark Grant, President and Chief Executive Officer of Lifeward. "We have built the clinical
- PROramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetSignificant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa
- SECSEC Form SD filed by Lifeward Ltd.SD - Lifeward Ltd. (0001607962) (Filer)
- SECSEC Form S-8 filed by Lifeward Ltd.S-8 - Lifeward Ltd. (0001607962) (Filer)
- SECSEC Form 10-Q filed by Lifeward Ltd.10-Q - Lifeward Ltd. (0001607962) (Filer)
- INSIDERChief Medical Officer Rose Keith Dale was granted 15,000 units of Ordinary Shares, increasing direct ownership by 720% to 17,083 units (SEC Form 4)4 - Lifeward Ltd. (0001607962) (Issuer)
- INSIDERNew insider Rose Keith Dale claimed ownership of 2,083 units of Ordinary Shares (SEC Form 3)3 - Lifeward Ltd. (0001607962) (Issuer)
- SECLifeward Ltd. filed SEC Form 8-K: Other Events8-K - Lifeward Ltd. (0001607962) (Filer)
- PRLifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed PlatformVeteran physician, medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience, mobility technologies, and metabolic disease Promotion reflects Lifeward's continued investment in clinical innovation, evidence generation, and patient outcomes across its expanding med-tech rehabilitation and biomed technology portfolio HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of
- SECSEC Form NT 10-Q filed by Lifeward Ltd.NT 10-Q - Lifeward Ltd. (0001607962) (Filer)
- SECLifeward Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Lifeward Ltd. (0001607962) (Filer)
LFWD FAQ
6 questionsWhere does LFWD stock trade?
Lifeward Ltd. (LFWD) is listed on NASDAQ.What sector and industry is LFWD in?
Lifeward Ltd. operates in the Health Care sector, Industrial Specialties industry.When did Lifeward Ltd. go public?
Lifeward Ltd. (LFWD) completed its IPO in 2014.What are analysts saying about LFWD?
Lifeward Ltd. has had 1 recent analyst action on file. The most recent action was from Laidlaw: Buy with a $1000.00 price target on 2025-02-10. Recent price targets cluster around $1000.00.What companies are similar to LFWD?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare LFWD side-by-side with any of them on Quantisnow.How can I track LFWD on Quantisnow?
Quantisnow aggregates Lifeward Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LFWD to receive live email and push alerts on every new disclosure.